Similar articles

• Direct oral anticoagulants in atrial fibrillation.

  Noll G, Noll S, Hürlimann D. Noll G, et al. Semin Hematol. 2014 Apr;51(2):139-46. doi: 10.1053/j.seminhematol.2014.04.001. Epub 2014 Apr 8. Semin Hematol. 2014. PMID: 24861798
• Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.

  Lane DA, Wood K. Lane DA, et al. Circulation. 2015 Apr 21;131(16):e412-5. doi: 10.1161/CIRCULATIONAHA.114.012808. Circulation. 2015. PMID: 25901074 Free PMC article. No abstract available.
• Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.

  Skjøth F, Larsen TB, Rasmussen LH, Lip GY. Skjøth F, et al. Thromb Haemost. 2014 May 5;111(5):981-8. doi: 10.1160/TH14-02-0118. Epub 2014 Feb 28. Thromb Haemost. 2014. PMID: 24577485
• New oral anticoagulant agents - general features and outcomes in subsets of patients.

  Schulman S. Schulman S. Thromb Haemost. 2014 Apr 1;111(4):575-82. doi: 10.1160/TH13-09-0803. Epub 2014 Jan 23. Thromb Haemost. 2014. PMID: 24452881 Review.
• Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.

  Berman JP, Halperin JL. Berman JP, et al. Hosp Pract (1995). 2013 Feb;41(1):37-48. doi: 10.3810/hp.2013.02.1006. Hosp Pract (1995). 2013. PMID: 23466966 Review.